• Cytokinetics published “Effect of Aficamten on Cardiac Structure and Function in Nonobstructive Hypertrophic Cardiomyopathy: The ACACIA-HCM CMR Study.”
• The presentation highlighted significantly greater improvements in exercise capacity and health status with aficamten versus placebo in the pivotal Phase 3 trial.
• Peak oxygen uptake showed a least-squares mean difference of 0.67 mL/kg/min versus placebo (P=0.003).
• The cardiac magnetic resonance substudy enrolled 69 patients; 61 (88.4%) completed baseline and week 36 scans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.